Equities

Theralase Technologies Inc

Theralase Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.285
  • Today's Change0.000 / 0.00%
  • Shares traded34.04k
  • 1 Year change+67.65%
  • Beta1.3490
Data delayed at least 15 minutes, as of Nov 14 2024 19:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Theralase Technologies Inc had revenues fall -6.00% from 1.14m to 1.07m, though the company grew net income from a loss of 5.24m to a smaller loss of 4.57m.
Gross margin49.00%
Net profit margin-478.72%
Operating margin-478.72%
Return on assets-130.29%
Return on equity-238.55%
Return on investment-204.79%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Theralase Technologies Inc fell by 1.46m. Cash Flow from Financing totalled 2.65m or 247.16% of revenues. In addition the company used 4.07m for operations while cash used for investing totalled 37.27k.
Cash flow per share-0.0182
Price/Cash flow per share--
Book value per share0.0069
Tangible book value per share0.0069
More ▼

Balance sheet in CADView more

Theralase Technologies Inc has a Debt to Total Capital ratio of 17.07%, a lower figure than the previous year's 17.88%.
Current ratio1.21
Quick ratio0.7723
Total debt/total equity0.2059
Total debt/total capital0.1707
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.